OQS
PTGX icon

Occudo Quantitative Strategies’s Protagonist Therapeutics PTGX Stock Holding History

Occudo Quantitative Strategies’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,281
Closed -$405K – 846
2025
Q1 		$405K Buy
+8,281
New +$347K 0.05% 412
2023
Q1 		– Sell
-10,198
Closed -$111K – 1143
2022
Q4 		$111K Sell
10,198
-10,689
-51% -$90.2K 0.01% 837
2022
Q3 		$176K Sell
20,887
-117,508
-85% -$1.11M 0.01% 980
2022
Q2 		$1.09M Buy
138,395
+115,035
+492% +$1.39M 0.09% 356
2022
Q1 		$553K Buy
+23,360
New +$658K 0.05% 603
2021
Q4 		– Sell
-23,876
Closed -$423K – 1221
2021
Q3 		$423K Buy
+23,876
New +$1.02M 0.05% 605

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Occudo Quantitative Strategies's PTGX Position: Q2 2025 in Review

Occudo Quantitative Strategies sold out of Protagonist Therapeutics (PTGX) in Q2 2025, closing a stake of 8,281 shares — an estimated $405K sold.

Occudo Quantitative Strategies first reported a position in PTGX in Q3 2021 and held it in 6 quarters. The position peaked at $1.09M in Q2 2022. 272 funds tracked by Wall St. Rank hold PTGX as of Q2 2025.

  • Occudo Quantitative Strategies reported no remaining Protagonist Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 8,281 Protagonist Therapeutics shares in Q2 2025, an estimated $405K.
  • Occudo Quantitative Strategies first reported a position in Protagonist Therapeutics in Q3 2021 and held it in 6 quarters.
  • Occudo Quantitative Strategies's Protagonist Therapeutics position peaked at $1.09M in Q2 2022.
  • 272 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2025.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2025, filed 14 Aug 2025.